Compare INTT & SPRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | INTT | SPRO |
|---|---|---|
| Founded | 1981 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 176.5M | 156.3M |
| IPO Year | 1997 | 2017 |
| Metric | INTT | SPRO |
|---|---|---|
| Price | $13.96 | $1.22 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $13.50 | N/A |
| AVG Volume (30 Days) | 147.0K | ★ 1.7M |
| Earning Date | 05-05-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 111.81 |
| EPS | ★ 0.06 | N/A |
| Revenue | $66,801,000.00 | ★ $66,802,000.00 |
| Revenue This Year | $15.82 | N/A |
| Revenue Next Year | $9.10 | $300.00 |
| P/E Ratio | $226.50 | ★ N/A |
| Revenue Growth | ★ 66.06 | 39.24 |
| 52 Week Low | $6.63 | $1.08 |
| 52 Week High | $20.00 | $3.08 |
| Indicator | INTT | SPRO |
|---|---|---|
| Relative Strength Index (RSI) | 47.54 | 31.65 |
| Support Level | $12.75 | $1.10 |
| Resistance Level | $15.34 | $1.28 |
| Average True Range (ATR) | 1.00 | 0.07 |
| MACD | 0.16 | 0.04 |
| Stochastic Oscillator | 73.09 | 48.57 |
inTest Corp is a supplier of test and process technology solutions for use in manufacturing and testing across a wide range of markets, including Semi, Auto/EV, Defense/Aerospace, Industrial, Life Sciences, Safety/Security, and Other. The Company has three operating segments, which are also its reportable segments and reporting units: Electronic Test, which generates the majority of its revenue and includes semiconductor test equipment, flying probe, and in-circuit testers; Environmental Technologies, which includes thermal test, process, and storage products; and Process Technologies, which includes induction heating and video imaging products. The Company generates the maximum revenue from the U.S.
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. It is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.